2014 Annual Report
MESSAGE FROM OUR CEO
DEAR MEMBERS OF THE ACORDA COMMUNITY:
In 2014, we made significant strides in our mission to develop therapies that restore function and improve the lives of people with neurological disorders. Our progress was enabled by our grounding in scientific, medical and business excellence, and our focus on three core value drivers: AMPYRA® commercial performance; clinical pipeline; and business development.
Read MoreAdvanced Pipeline
Read MoreCivitas Therapeutics Acquisition
In October 2014, we completed the acquisition of Civitas Therapeutics, a privately-held biotechnology company with two novel neurology products in development. There are three aspects that made this transaction very attractive to us, and that have the potential to deliver substantial value over time.
Read More2014 HIGHLIGHTS
2015 Guidance
Our guidance range reflects continued confidence in the growth of AMPYRA, increasing from $366.2 million in net sales from 2014.
CVT-301, dalfampridine in chronic post-stroke walking deficits (PSWD) and PLUMIAZ.
Acorda has 5 clinical-stage programs that have potential to improve the lives of millions of patients and drive shareholder value.
We place a high priority on managing SG&A; our guidance represents a minimal increase over 2014 despite added infrastructure related to the Civitas acquisition.
Management Team
Board of Directors
- Ron Cohen, M.D.
Founder - Peder K. Jensen, M.D.
Board Member since 2011 - Sandra Panem, Ph.D.
Board Member since 1998 - Steven M. Rauscher
Board Member since 2005 - Barry Greene
Board Member since 2007 - John P. Kelley
Board Member since 2008 - Lorin J. Randall
Board Member since 2006 - Ian F. Smith
Board Member since 2007